Trial Profile
A Phase 1/2 Study of Nab-Sirolimus With Pazopanib (VOTRIENT®) in Patients With Advanced Nonadipocytic Soft-Tissue Sarcomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sirolimus (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2023 Results (n=19) assessing safety and efficacy of sirolimus combined with pazopanib in patients with advanced soft tissue sarcoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 25 May 2023 Results presented in an Aadi Media Release.
- 26 Apr 2023 According to an Aadi media release, data from this trial will be presented at the upcoming 2023 American Society of Clinical Oncology Annual Meeting.